Status:
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Lead Sponsor:
AstraZeneca
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squam...
Detailed Description
This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based ...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
November 18 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 8 2029
Estimated Enrollment :
880 Patients enrolled
Trial Details
Trial ID
NCT06692738
Start Date
November 18 2024
End Date
October 8 2029
Last Update
February 25 2026
Active Locations (300)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Tucson, Arizona, United States, 85724
2
Research Site
Springdale, Arkansas, United States, 72762
3
Research Site
Anaheim, California, United States, 92801
4
Research Site
Beverly Hills, California, United States, 90211